-
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndr NDA submission supported by positive Phase 3 data recently published in JAMA Neurology. Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and...资讯2026-06-19
-
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second qu...资讯2026-06-19
最热
推荐
- 精医巨献,美丽升级,2024海峡整形技术升级发布月
- 《杨海伦:艺界璀璨之星,奏响跨中法文化交流的华丽乐章》
- X GAMES CHINA 2024滑板U池巡回赛武汉站圆满落幕 桂茁然领跑 巴西滑手Iago Mafalhaes献上惊喜!
- 科大讯飞登上Nature子刊:AI解化学奥赛题超越人类选手平均水平
- 喆贞软件:以技术驱动区域数字化升级,打造政务与产业转型新标杆
- “比萨专家”必胜客旗下新模式Pizzeria餐厅,首店落户上海
- Denodo University Challenge Now Open: Data and AI for Real-World Impact
- 2025第52届中国国际医疗器械(山东)博览会即将启幕
- Picus Security Hosts State of BAS 2025 to Redefine Attack Simulation Through AI
- 一部手机看舌头,人人都是老中医,分文不花AI免费,无需久病成良医
